PYC Therapeutics (ASX:PYC) Receives Approval for Dose Escalation in ADOA Clinical Trial
PYC Therapeutics (ASX:PYC) receives approval to escalate dosing in its ADOA clinical trial, advancing development of its PYC-001 drug candidate.
Category: ASX-PYC
PYC Therapeutics Limited
PYC Therapeutics (ASX:PYC) Announces Q1 2025 Shareholder Update
PYC Therapeutics (ASX:PYC) extends cash runway to over $200m and advances polycystic kidney disease program in Q1 2025.